QTTB
Q32 Bio Inc.
Price Chart
Latest Quote
$11.90
-1.01 (-7.82%)
Current Price
| Previous Close | $12.91 |
| Open | $13.15 |
| Day High | $13.37 |
| Day Low | $11.75 |
| Volume | 407,796 |
Stock Information
| Shares Outstanding | 16.96M |
| Total Debt | $13.65M |
| Cash Equivalents | $50.75M |
| Revenue | $53.74M |
| Net Income | $33.24M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $201.78M |
| P/E Ratio | 4.28 |
| EPS (TTM) | $2.78 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $164.68M |
| Sales | $53.74M |
| Income | $33.24M |
| Book/sh | $3.17 |
| Cash/sh | $2.99 |
| Employees | 22 |
Financial Ratios
| Quick Ratio | 4.81 |
| Current Ratio | 5.36 |
| Debt/Eq | 29.46 |
Returns & Margins
| ROA | 18.75% |
| ROE | 157.18% |
| Gross Margin | 71.62% |
| Operating Margin | 39.84% |
| Profit Margin | 61.86% |
Ownership
| Insider Ownership | 3.93% |
| Institutional Ownership | 107.95% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.22 |
| P/S | 3.75 |
| P/B | 3.76 |
Analyst Data
| Recommendation | none |
| Target Price | $14.25 |
Technical Indicators
| SMA20 | $11.44 |
| SMA50 | $8.02 |
| SMA200 | $4.69 |
| RSI | 54.90 |
| ATR | 1.5622 |
| Shares Float | 1.55M |
| Short Float | 10.58% |
| Short Ratio | 0.66 |
| Volatility | -0.23 |
| Rel Volume | 0.25 |
Performance History
| Week | -6.30% |
| Month | +96.05% |
| Quarter | +78.41% |
| 6 Months | +313.19% |
| YTD | +245.93% |
| Year | +634.57% |
| 3 Years | -36.43% |
| 5 Years | -90.78% |
| 10 Years | -96.46% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $11.90 | 407,800 |
| 2026-06-17 | $12.91 | 251,500 |
| 2026-06-16 | $12.75 | 427,800 |
| 2026-06-15 | $12.86 | 361,100 |
| 2026-06-12 | $12.64 | 326,300 |
| 2026-06-11 | $12.70 | 438,000 |
| 2026-06-10 | $12.87 | 645,000 |
| 2026-06-09 | $11.89 | 628,600 |
| 2026-06-08 | $12.03 | 660,800 |
| 2026-06-05 | $13.11 | 764,800 |
| 2026-06-04 | $14.00 | 1,055,100 |
| 2026-06-03 | $12.19 | 537,700 |
| 2026-06-02 | $12.64 | 777,800 |
| 2026-06-01 | $11.66 | 1,072,700 |
| 2026-05-29 | $11.05 | 1,200,400 |
| 2026-05-28 | $10.31 | 1,278,700 |
| 2026-05-27 | $12.85 | 21,152,800 |
| 2026-05-26 | $7.09 | 297,700 |
| 2026-05-22 | $5.80 | 623,700 |
| 2026-05-21 | $5.50 | 181,000 |
| 2026-05-20 | $5.67 | 284,300 |
| 2026-05-19 | $6.07 | 302,900 |
About Q32 Bio Inc.
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiÂinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb  CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts.
đ° Latest News
QTTB Stock Hits 18-Month High, Heads Toward Recording Its Best Ever Month â Whatâs Driving The Investor Optimism?
Stocktwits âĸ 2026-05-27T17:55:39Z
Q32 Bio Secures $55 Million Private Placement to Advance Alopecia Areata Pipeline (QTTB)
InvestorsHub âĸ 2026-05-27T15:53:57Z
Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet
Zacks âĸ 2026-05-26T13:55:02Z
Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to Trade
Zacks âĸ 2026-05-08T13:55:03Z
Q32 Bio Gears Up to Report Q1 Earnings: What's in the Cards?
Zacks âĸ 2026-04-30T19:10:00Z
Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?
Zacks âĸ 2026-03-30T13:55:02Z
Best Momentum Stocks to Buy for March 27th
Zacks âĸ 2026-03-27T14:15:00Z
New Strong Buy Stocks for March 27th
Zacks âĸ 2026-03-27T08:35:00Z
Q32 Bio (QTTB) Upgraded to Strong Buy: Here's What You Should Know
Zacks âĸ 2026-03-19T16:00:04Z
Best Momentum Stocks to Buy for March 19th
Zacks âĸ 2026-03-19T14:15:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $53,737,000 | $0 | $-6,651,000 | $6,651,000 |
| Operating Revenue | $53,737,000 | $0 | $-6,651,000 | $6,651,000 |
| Expenses | ||||
| Interest Expense | $1,100,000 | $1,100,000 | - | - |
| Total Expenses | $36,835,000 | $66,102,000 | $41,604,000 | $45,876,000 |
| Other Income Expense | $11,819,000 | $17,215,000 | $-5,170,000 | $-3,522,000 |
| Other Non Operating Income Expenses | $82,000 | $2,025,000 | $1,023,000 | $-1,120,000 |
| Net Non Operating Interest Income Expense | $1,100,000 | $2,800,000 | - | - |
| Interest Expense Non Operating | $1,100,000 | $1,100,000 | - | - |
| Operating Expense | $36,835,000 | $66,102,000 | $41,604,000 | $45,876,000 |
| General And Administrative Expense | $17,679,000 | $17,959,000 | $9,875,000 | $10,062,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Net Interest Income | $1,100,000 | $2,800,000 | - | - |
| Interest Income | $2,200,000 | $3,900,000 | - | - |
| Normalized Income | $18,084,000 | $-59,733,100 | $-48,850,530 | $-40,407,000 |
| Net Income From Continuing And Discontinued Operation | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Total Operating Income As Reported | $16,902,000 | $-66,102,000 | $-48,255,000 | $-39,225,000 |
| Net Income Common Stockholders | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Net Income | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Net Income Including Noncontrolling Interests | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Net Income Continuous Operations | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-1,625,000 | $0 | - |
| Pretax Income | $29,821,000 | $-46,087,000 | $-53,425,000 | $-42,747,000 |
| Special Income Charges | $11,737,000 | $-700,000 | - | - |
| Interest Income Non Operating | $2,200,000 | $3,900,000 | - | - |
| Operating Income | $16,902,000 | $-66,102,000 | $-48,255,000 | $-39,225,000 |
| Average Dilution Earnings | - | $-15,800,000 | - | - |
| Per Share | ||||
| Diluted EPS | $2.42 | $-6.58 | $-4.51 | $-3.59 |
| Basic EPS | $2.42 | $-5.12 | $-4.51 | $-3.59 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $3,189,900 | $-1,300,530 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $19,575,000 | $-59,690,000 | $-41,563,000 | $-36,453,000 |
| Total Unusual Items | $11,737,000 | $15,190,000 | $-6,193,000 | $-2,402,000 |
| Total Unusual Items Excluding Goodwill | $11,737,000 | $15,190,000 | $-6,193,000 | $-2,402,000 |
| Reconciled Depreciation | $391,000 | $487,000 | $499,000 | $370,000 |
| EBITDA (Bullshit earnings) | $31,312,000 | $-44,500,000 | $-47,756,000 | $-38,855,000 |
| EBIT | $30,921,000 | $-44,987,000 | $-48,255,000 | $-39,225,000 |
| Diluted Average Shares | $12,314,796 | $9,657,696 | $11,929,528 | $11,929,528 |
| Basic Average Shares | $12,300,568 | $9,320,884 | $11,929,528 | $11,929,528 |
| Diluted NI Availto Com Stockholders | $29,821,000 | $-63,533,000 | $-53,743,000 | $-42,809,000 |
| Tax Provision | $0 | $21,000 | $318,000 | $62,000 |
| Gain On Sale Of Ppe | $11,737,000 | $0 | - | - |
| Research And Development | $19,156,000 | $48,143,000 | $31,729,000 | $35,814,000 |
| Selling General And Administration | $17,679,000 | $17,959,000 | $9,875,000 | $10,062,000 |
| Other Gand A | $17,679,000 | $17,959,000 | $9,875,000 | $10,062,000 |
| Write Off | - | $700,000 | - | - |
| Gain On Sale Of Security | - | $15,890,000 | $-6,193,000 | $-2,402,000 |
Fetched: 2026-06-16
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $42,014,000 | $5,675,000 | $-182,921,000 | $-130,712,000 |
| Total Assets | $61,776,000 | $92,332,000 | $47,057,000 | $61,774,000 |
| Total Non Current Assets | $6,726,000 | $10,455,000 | $18,341,000 | $14,921,000 |
| Other Non Current Assets | $647,000 | $647,000 | $5,670,000 | $5,755,000 |
| Non Current Prepaid Assets | $0 | $116,000 | $676,000 | - |
| Current Assets | $55,050,000 | $81,877,000 | $28,716,000 | $46,853,000 |
| Other Current Assets | $20,000 | $396,000 | $83,000 | $146,000 |
| Prepaid Assets | $1,341,000 | $2,961,000 | $2,261,000 | $1,750,000 |
| Receivables | $5,392,000 | $555,000 | $755,000 | $1,064,000 |
| Other Receivables | $4,837,000 | - | - | $116,000 |
| Taxes Receivable | $555,000 | $555,000 | $755,000 | $948,000 |
| Cash Cash Equivalents And Short Term Investments | $48,297,000 | $77,965,000 | $25,617,000 | $43,893,000 |
| Cash And Cash Equivalents | $48,297,000 | $77,965,000 | $25,617,000 | $43,893,000 |
| Non Current Deferred Assets | - | $0 | $3,912,000 | - |
| Debt | ||||
| Total Debt | $15,344,000 | $18,901,000 | $50,840,000 | $44,731,000 |
| Long Term Debt And Capital Lease Obligation | $8,416,000 | $15,192,000 | $49,424,000 | $11,858,000 |
| Long Term Debt | $3,473,000 | $9,556,000 | $43,176,000 | $5,072,000 |
| Current Debt And Capital Lease Obligation | $6,928,000 | $3,709,000 | $1,416,000 | $32,873,000 |
| Current Debt | $6,235,000 | $3,097,000 | $878,000 | $32,402,000 |
| Other Current Borrowings | $6,235,000 | $3,097,000 | $878,000 | $32,402,000 |
| Net Debt | - | - | $18,437,000 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,762,000 | $86,657,000 | $229,978,000 | $192,486,000 |
| Total Non Current Liabilities Net Minority Interest | $8,416,000 | $70,192,000 | $215,869,000 | $134,621,000 |
| Current Liabilities | $11,346,000 | $16,465,000 | $14,109,000 | $57,865,000 |
| Payables And Accrued Expenses | $1,932,000 | $7,074,000 | $9,690,000 | $7,670,000 |
| Payables | $879,000 | $2,989,000 | $3,784,000 | $2,005,000 |
| Accounts Payable | $879,000 | $2,989,000 | $3,468,000 | $1,435,000 |
| Other Non Current Liabilities | - | $55,000,000 | $55,000,000 | - |
| Other Current Liabilities | - | $2,900,000 | - | - |
| Total Tax Payable | - | $0 | $316,000 | $570,000 |
| Non Current Deferred Liabilities | - | - | - | $11,318,000 |
| Current Deferred Liabilities | - | - | - | $14,531,000 |
| Interest Payable | - | - | - | $376,000 |
| Equity | ||||
| Common Stock Equity | $42,014,000 | $5,675,000 | $-182,921,000 | $-130,712,000 |
| Total Equity Gross Minority Interest | $42,014,000 | $5,675,000 | $-182,921,000 | $-130,712,000 |
| Stockholders Equity | $42,014,000 | $5,675,000 | $-182,921,000 | $-130,712,000 |
| Retained Earnings | $-204,993,000 | $-234,814,000 | $-187,081,000 | $-133,338,000 |
| Long Term Equity Investment | $0 | $2,600,000 | $0 | - |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $0 | - |
| Preferred Securities Outside Stock Equity | - | $0 | $111,445,000 | $111,445,000 |
| Preferred Stock Equity | - | - | - | $111,445,000 |
| Other | ||||
| Ordinary Shares Number | $12,858,047 | $12,197,615 | $11,929,528 | $11,929,528 |
| Share Issued | $12,858,047 | $12,197,615 | $11,929,528 | $11,929,528 |
| Tangible Book Value | $42,014,000 | $5,675,000 | $-182,921,000 | $-130,712,000 |
| Invested Capital | $51,722,000 | $18,328,000 | $-138,867,000 | $-93,238,000 |
| Working Capital | $43,704,000 | $65,412,000 | $14,607,000 | $-11,012,000 |
| Capital Lease Obligations | $5,636,000 | $6,248,000 | $6,786,000 | $7,257,000 |
| Total Capitalization | $45,487,000 | $15,231,000 | $-139,745,000 | $-125,640,000 |
| Additional Paid In Capital | $247,005,000 | $240,487,000 | $4,159,000 | $2,625,000 |
| Capital Stock | $2,000 | $2,000 | $1,000 | $1,000 |
| Common Stock | $2,000 | $2,000 | $1,000 | $1,000 |
| Preferred Stock | $0 | $0 | - | $111,445,000 |
| Long Term Capital Lease Obligation | $4,943,000 | $5,636,000 | $6,248,000 | $6,786,000 |
| Current Capital Lease Obligation | $693,000 | $612,000 | $538,000 | $471,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,486,000 | $2,782,000 | $3,003,000 | $2,791,000 |
| Current Accrued Expenses | $1,053,000 | $4,085,000 | $5,906,000 | $5,665,000 |
| Investments And Advances | $0 | $2,600,000 | $0 | - |
| Net PPE | $6,079,000 | $7,092,000 | $8,083,000 | $9,166,000 |
| Accumulated Depreciation | $-1,844,000 | $-1,453,000 | $-966,000 | $-467,000 |
| Gross PPE | $7,923,000 | $8,545,000 | $9,049,000 | $9,633,000 |
| Leases | $1,001,000 | $1,001,000 | $940,000 | $935,000 |
| Other Properties | $6,482,000 | $7,104,000 | $7,683,000 | $8,272,000 |
| Machinery Furniture Equipment | $440,000 | $440,000 | $426,000 | $426,000 |
| Properties | $0 | $0 | $0 | $0 |
| Non Current Deferred Revenue | - | - | - | $11,318,000 |
| Current Deferred Revenue | - | - | - | $14,531,000 |
Fetched: 2026-06-16
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-33,543,000 | $-67,790,000 | $-18,682,000 | $-13,442,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-33,543,000 | $-67,715,000 | $-18,677,000 | $-10,957,000 |
| Cash Flow From Continuing Operating Activities | $-33,543,000 | $-67,715,000 | $-18,677,000 | $-10,957,000 |
| Operating Gains Losses | $-11,737,000 | $1,625,000 | - | $23,000 |
| Investing Activities | ||||
| Investing Cash Flow | $7,000,000 | $19,925,000 | $-5,000 | $-2,466,000 |
| Cash Flow From Continuing Investing Activities | $7,000,000 | $19,925,000 | $-5,000 | $-2,466,000 |
| Net Other Investing Changes | $7,000,000 | - | - | - |
| Capital Expenditure | - | $-75,000 | $-5,000 | $-2,485,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $42,000,000 | $0 | $0 |
| Financing Cash Flow | $-3,125,000 | $95,138,000 | $406,000 | $30,069,000 |
| Cash Flow From Continuing Financing Activities | $-3,125,000 | $95,138,000 | $406,000 | $30,069,000 |
| Net Common Stock Issuance | $0 | $42,000,000 | $0 | $69,000 |
| Common Stock Issuance | $0 | $42,000,000 | $0 | $69,000 |
| Net Other Financing Charges | - | $44,444,000 | - | - |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-3,125,000 | $0 | $-5,200,000 | - |
| Issuance Of Debt | $0 | $7,000,000 | $5,500,000 | $30,000,000 |
| Interest Paid Supplemental Data | $961,000 | $856,000 | $422,000 | - |
| End Cash Position | $48,944,000 | $78,612,000 | $31,264,000 | $49,540,000 |
| Beginning Cash Position | $78,612,000 | $31,264,000 | $49,540,000 | $32,894,000 |
| Changes In Cash | $-29,668,000 | $47,348,000 | $-18,276,000 | $16,646,000 |
| Proceeds From Stock Option Exercised | $0 | $1,694,000 | $106,000 | $69,000 |
| Net Issuance Payments Of Debt | $-3,125,000 | $7,000,000 | $300,000 | $30,000,000 |
| Net Long Term Debt Issuance | $-3,125,000 | $7,000,000 | $300,000 | - |
| Long Term Debt Payments | $-3,125,000 | $0 | $-5,200,000 | - |
| Long Term Debt Issuance | $0 | $7,000,000 | $5,500,000 | - |
| Net Investment Purchase And Sale | $0 | $20,000,000 | $0 | - |
| Sale Of Investment | $0 | $20,000,000 | $0 | - |
| Net PPE Purchase And Sale | $0 | $-75,000 | $-5,000 | $-2,466,000 |
| Purchase Of PPE | $0 | $-75,000 | $-5,000 | $-2,485,000 |
| Change In Working Capital | $-4,038,000 | $-9,637,000 | $26,315,000 | $26,943,000 |
| Change In Other Current Liabilities | $-612,000 | $-1,542,000 | $54,529,000 | $-409,000 |
| Change In Other Current Assets | $116,000 | $386,000 | $-4,503,000 | $195,000 |
| Change In Payables And Accrued Expense | $-5,438,000 | $-8,757,000 | $2,232,000 | $2,517,000 |
| Change In Accrued Expense | $-3,328,000 | $-7,714,000 | $199,000 | $3,758,000 |
| Change In Payable | $-2,110,000 | $-1,043,000 | $2,033,000 | $-1,241,000 |
| Change In Account Payable | $-2,110,000 | $-1,043,000 | $2,033,000 | $-1,241,000 |
| Change In Prepaid Assets | $1,896,000 | $276,000 | $-94,000 | $-1,209,000 |
| Other Non Cash Items | $-53,309,000 | $-1,407,000 | $631,000 | $876,000 |
| Stock Based Compensation | $5,255,000 | $4,386,000 | $1,428,000 | $1,238,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $-15,890,000 | $6,193,000 | $2,402,000 |
| Asset Impairment Charge | $74,000 | $675,000 | $0 | - |
| Amortization Of Securities | $0 | $-221,000 | $0 | - |
| Depreciation Amortization Depletion | $391,000 | $487,000 | $499,000 | $370,000 |
| Depreciation And Amortization | $391,000 | $487,000 | $499,000 | $370,000 |
| Depreciation | $391,000 | $487,000 | $499,000 | $370,000 |
| Earnings Losses From Equity Investments | $0 | $1,625,000 | $0 | - |
| Net Income From Continuing Operations | $29,821,000 | $-47,733,000 | $-53,743,000 | $-42,809,000 |
| Change In Other Working Capital | - | - | $-25,849,000 | $25,849,000 |
| Net Short Term Debt Issuance | - | - | - | $30,000,000 |
| Short Term Debt Issuance | - | - | - | $30,000,000 |
| Sale Of PPE | - | - | - | $19,000 |
| Gain Loss On Sale Of PPE | - | - | - | $23,000 |
Fetched: 2026-06-16